What the FDA labels say about taking them together
Apomorphine and granisetron
Apomorphine's FDA label of February 24, 2022 names granisetron in its contraindications section; the granisetron labels PlainMeds reads (3) do not name apomorphine. The apomorphine label: “CONTRAINDICATIONS ONAPGO is contraindicated in patients: Using concomitant 5HT 3 antagonists, including antiemetics and alosetron.”
Check it at the source: the apomorphine FDA label on DailyMed (effective February 24, 2022, TruPharma, LLC); the granisetron FDA label on DailyMed (effective August 31, 2017, Mylan Institutional LLC).
What does the apomorphine label say about granisetron?
Apomorphine label, contraindicationsCONTRAINDICATIONS Apomorphine hydrocloride is contraindicated in patients: Using concomitant drugs of the 5HT 3 antagonist class including antiemetics (e.g., ondansetron, granisetron, dolasetron, palonosetron) and alosetron [see Drug Interactions (7.1) ].
Apomorphine label, drug interactionsDRUG INTERACTIONS Concomitant use of antihypertensive medications and vasodilators: increased risk for hypotension, myocardial infarction, pneumonia, falls, and injuries ( 7.2 ) Dopamine antagonists such as neuroleptics or metoclopramide, may diminish the effectiveness of apomorphine hydrocloride ( 7.4 ) 7.1 5HT 3 Antagonists Based on reports of profound hypotension and loss of consciousness when apomorphine hydrocloride was administered with ondansetron, the concomitant use of apomorphine hydrocloride with 5HT 3 antagonists including antiemetics (for example, ondansetron, granisetron, dolasetron, palonosetron) and alosetron, is contraindicated.
Source: FDA drug label (Onapgo, NDA214056), MDD US Operations, LLC, a subsidiary of Supernus Pharmaceuticals, Inc, effective July 10, 2026 (SPL set f3552b6e-5ae7-4993-aa1a-e399c4a7080a), via openFDA
Source: FDA drug label (apomorphine hydrocloride), ANDA212025 (Tp Anda Holdings), as published by TruPharma, LLC, effective February 24, 2022 (SPL set aedf70e4-1949-44bc-bf1b-0f282c4f0705), via openFDA; the full label on DailyMed
What does the granisetron label say about apomorphine?
Granisetron's label (effective August 31, 2017) and its 2 other brand-application labels do not name apomorphine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Granisetron Hydrochloride), Mylan Institutional LLC, effective August 31, 2017 (SPL set 8d88adba-7f5e-4e97-84b3-6ca8ec98c023), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Apomorphine | Granisetron | |
|---|---|---|
| Labeled for | Parkinson's disease | Nausea and vomiting |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $1.31 per tablet 1 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once